It’s important to lay strong foundations for successful drug discovery at this first stage of the process. Our integrated target identification and validation platform combines AI with expert insights, and rigorous lab validation to guide targets through robust evaluation, ready for hit discovery.
Validated, high-quality hits, delivered through integrated technologies and expert collaboration, give you a confident starting point for faster drug discovery.
Turning promising leads into clinical candidates with speed, precision, and the scientific expertise to generate high-quality data and deliver real patient impact.
Delivering integrated, modality-agnostic drug discovery to tackle complex biology, accelerate development, and advance innovative therapies with confidence.
Advancing next-generation ADCs through payload-focused design, integrated expertise, and collaborative innovation to deliver safer, more selective therapies.
Driving biologics innovation through integrated design, structural biology, and multidisciplinary expertise to accelerate next-generation therapies from concept to clinic.
Combining deep therapeutic expertise with translational insight to design strategies, reduce risk, and accelerate discovery programs toward clinical success.
Accelerating oncology drug discovery through integrated expertise, innovative modalities, and translational insight to deliver candidates with real clinical impact.
Driving immunology and inflammation drug discovery through tailored assays, translational models, and integrated expertise for faster clinical success.
Advancing CNS drug discovery through integrated models, translational biomarkers, and multidisciplinary expertise to overcome complexity and accelerate therapeutic innovation.
Designing and advancing differentiated small-molecule therapies for obesity and diabetes through integrated expertise, mechanistic insight, and translational strategies.
Inobrodib, an exciting, first-in-class oral anti-cancer drug in clinical development by CellCentric, was collaboratively designed, synthesised and supported on its pre-clinical journey by an integrated project team at Sygnature Discovery. Inobrodib is now showing promising results in Phase I and II trials for multiple myeloma and other cancer types.
It’s important to lay strong foundations for successful drug discovery at this first stage of the process. Our integrated target identification and validation platform combines AI with expert insights, and rigorous lab validation to guide targets through robust evaluation, ready for hit discovery.
Validated, high-quality hits, delivered through integrated technologies and expert collaboration, give you a confident starting point for faster drug discovery.
Turning promising leads into clinical candidates with speed, precision, and the scientific expertise to generate high-quality data and deliver real patient impact.
Delivering integrated, modality-agnostic drug discovery to tackle complex biology, accelerate development, and advance innovative therapies with confidence.
Advancing next-generation ADCs through payload-focused design, integrated expertise, and collaborative innovation to deliver safer, more selective therapies.
Driving biologics innovation through integrated design, structural biology, and multidisciplinary expertise to accelerate next-generation therapies from concept to clinic.
Combining deep therapeutic expertise with translational insight to design strategies, reduce risk, and accelerate discovery programs toward clinical success.
Accelerating oncology drug discovery through integrated expertise, innovative modalities, and translational insight to deliver candidates with real clinical impact.
Driving immunology and inflammation drug discovery through tailored assays, translational models, and integrated expertise for faster clinical success.
Advancing CNS drug discovery through integrated models, translational biomarkers, and multidisciplinary expertise to overcome complexity and accelerate therapeutic innovation.
Designing and advancing differentiated small-molecule therapies for obesity and diabetes through integrated expertise, mechanistic insight, and translational strategies.
Inobrodib, an exciting, first-in-class oral anti-cancer drug in clinical development by CellCentric, was collaboratively designed, synthesised and supported on its pre-clinical journey by an integrated project team at Sygnature Discovery. Inobrodib is now showing promising results in Phase I and II trials for multiple myeloma and other cancer types.
Obesity, type 2 diabetes and related metabolic diseases are driving a global health crisis. Even with the rise of GLP-1s and incretin-based therapies, many patients face challenges with long-term weight management, treatment access, and polypharmacy. Sygnature Discovery brings together integrated discovery teams to design, profile and advance differentiated small-molecule therapies for obesity and metabolic disease from early target exploration through to preclinical candidate nomination.
Additional compounds advanced into pre- clinical development
Expertise spanning metabolic GPCRs and complex membrane-bound targets
supporting your research
Metabolic diseases involve complex networks of hormones, receptors and signalling pathways across multiple organs. Delivering effective, lasting therapies takes more than a potent molecule, it requires a discovery strategy that connects mechanism, pharmacology and translation.
Our scientists work across the entire metabolic disease discovery spectrum, including obesity, type 2 diabetes and associated complications such as NAFLD/MASH and diabetic nephropathy. Co-located medicinal chemists, DMPK experts, bioscientists, structural biologists and in vivo pharmacologists collaborate to:
• Identify and validate novel targets, including complex membrane-bound receptors and transporters
• Design fit-for-purpose in vitro, ex vivo and in vivo models that reflect human disease biology
• Integrate PK, PD and biomarker data to guide dose selection and translation
By combining mechanistic insight with iterative DMTA cycles, we deliver decision-ready data that de-risks your pipeline and moves promising programs toward the clinic with confidence.
Our Metabolic Disease Discovery Capabilities
Cell Line Generation & Cell-Based Assays
Designing the right cell line is the foundation of successful metabolic drug discovery. Our cellular pharmacology team builds well-characterized, stable expression systems that…
Previously “uncrystallizable” metabolic receptors, particularly GPCRs, can now be visualized at high resolution through cryo -EM. Our team routinely solves structures…
Obesity-specific DMPK challenges require careful balance of efficacy, safety, and variability in drug distribution. Our teams account for altered PK profiles…
Our integrated in vitro, ex vivo, and in vivo platform builds a unified understanding of metabolic biology. Capabilities include obesity and diabetes models…
Why Choose Sygnature Discovery for Metabolic Disease Support?
Sygnature Discovery offers an integrated, end-to-end approach to metabolic disease drug discovery, combining medicinal chemistry, DMPK, bioscience, structural biology and in vivo pharmacology under one roof. Our teams bring deep expertise in complex metabolic pathways and challenging target classes such as GPCRs and transporters, supported by bespoke cell lines, structural insight and robust screening platforms.
With a proven track record across obesity, type 2 diabetes and related comorbidities, we unify mechanism, pharmacology and translational biomarkers within cohesive DMTA cycles to generate high-quality, decision-ready data. Above all, we take a collaborative and strategic approach, shaping each program around your scientific goals to deliver differentiated, clinically meaningful small-molecule therapies.
Key Benefits
Tailored to your goals
Programs are customized to your target, indication and risk profile from focused assay development to fully integrated discovery campaigns.
Proven success with challenging targets
We have deep experience in membrane-bound receptors and complex metabolic pathways, supporting programs that span first-in-class targets and differentiation within crowded mechanisms.
Efficiency that saves time and costs
Co-located teams, automation and streamline workflows enable faster iteration, clear decision points and reduced timelines from hit to candidate.
Case Studies
Trusted by customers worldwide
Our customers tell us that we act as an extension of their team and provide high quality expertise at every stage of the drug discovery process. Whether we’re supporting you through the entire process, or just a part of it, our goal isn’t simply to move you to the next stage it’s to lay the foundations for a successfully marketed drug.
From Lead to Pre-Candidate Nomination in 18 Months
Progressing from lead to pre candidate nomination in less than half the industry standard timeline, this program shows how connected scientific teams and real time insight can accelerate complex discovery.
Many intriguing drug discovery programmes begin life at start-up biotech companies. Yet at the outset, these new organisations rarely have the resources or laboratory set-up immediately available to turn their ground-breaking ideas into a new medicine.
Rapid creation of ideas using generative AI (GenAI) with Iktos Makya
Leading generative artificial intelligence (GenAI) algorithms for de novo design are being used routinely within our medicinal chemistry programmes to enable rapid idea generation to address project objectives.
Fragment-based hit discovery for the epigenetic target, BRD3
Fragment-based drug discovery allows a wide section of chemical space to be interrogated with a relatively small but diverse library of small molecules.
Metaflammation fuels the global rise of metabolic diseases, including obesity and type 2 diabetes. Explore the intricate connection between chronic inflammation and these conditions, uncovering potential pharmacological strategies for managing meta-inflammation.
Over the last decade, GLP-1 therapies have transformed diabetes and obesity treatment. Discover the potential of small molecules in this field and their role in revolutionizing treatment options and improving patient outcomes.
